公开(公告)号：US10954233B2

公开(公告)日：2021-03-23

申请号：US16330820

申请日：2017-09-06

Applicant: Novartis AG

Inventor： Phillip Alper ,  Jonathan Deane ,  Songchun Jiang ,  Tao Jiang ,  Thomas Knoepfel ,  Pierre-Yves Michellys ,  Daniel Mutnick ,  Wei Pei ,  Peter Syka ,  Guobao Zhang ,  Yi Zhang

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61P17/06 ,  A61P1/16 ,  A61P37/06 ,  A61P19/02 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

公开(公告)号：US20190105309A1

公开(公告)日：2019-04-11

申请号：US16211139

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Thomas Knoepfel ,  Catherine Leblanc ,  Robert Mah

IPC: A61K31/444 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US10786492B2

公开(公告)日：2020-09-29

申请号：US16211139

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Thomas Knoepfel ,  Catherine Leblanc ,  Robert Mah

IPC: C07D401/12 ,  C07D401/14 ,  A61K31/444 ,  A61K31/4427 ,  C07D213/75 ,  C07D405/14 ,  A61P35/00 ,  A61K31/497

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US10130629B2

公开(公告)日：2018-11-20

申请号：US15561209

申请日：2016-03-23

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Jorge Garcia Fortanet ,  Pascal Furet ,  Diana Graus Porta ,  Nafeeza Hafeez ,  Bo Han ,  Thomas Knoepfel ,  Matthew J. LaMarche ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Dale Porter ,  Can Wang ,  Markus Wartmann ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/496 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.